Acuta Capital Partners as of June 30, 2021
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 37 positions in its portfolio as reported in the June 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Celldex Therapeutics Com New (CLDX) | 19.9 | $50M | 1.5M | 33.44 | |
| Vistagen Therapeutics Com New | 14.8 | $37M | 12M | 3.15 | |
| Apellis Pharmaceuticals (APLS) | 4.1 | $10M | 161k | 63.20 | |
| Arrowhead Pharmaceuticals (ARWR) | 3.6 | $8.9M | 108k | 82.82 | |
| Bcls Acquisition Corp Com Cl A | 3.5 | $8.9M | 843k | 10.53 | |
| Verastem | 3.3 | $8.2M | 2.0M | 4.07 | |
| Iveric Bio | 3.2 | $7.9M | 1.3M | 6.31 | |
| Xenon Pharmaceuticals (XENE) | 3.1 | $7.8M | 417k | 18.62 | |
| Apricus Biosciences | 3.0 | $7.6M | 2.9M | 2.64 | |
| Kura Oncology (KURA) | 2.9 | $7.4M | 353k | 20.85 | |
| Essa Pharma Com New (EPIX) | 2.7 | $6.7M | 233k | 28.57 | |
| Clearside Biomedical (CLSD) | 2.6 | $6.4M | 1.3M | 4.87 | |
| Fulcrum Therapeutics (FULC) | 2.5 | $6.3M | 604k | 10.48 | |
| Vincerx Pharma Com New (VINC) | 2.5 | $6.2M | 478k | 12.99 | |
| Cyteir Therapeutics | 2.4 | $5.9M | 278k | 21.40 | |
| Jiya Acquisition Corp Com Cl A | 2.2 | $5.6M | 563k | 9.94 | |
| Athira Pharma (ATHA) | 1.7 | $4.4M | 427k | 10.24 | |
| Aligos Therapeutics (ALGS) | 1.7 | $4.4M | 214k | 20.39 | |
| Selecta Biosciences (RNAC) | 1.7 | $4.3M | 1.0M | 4.18 | |
| Chimerix (CMRX) | 1.6 | $4.1M | 509k | 8.00 | |
| Health Sciences Acq Corp 2 Ord Shs | 1.6 | $4.0M | 393k | 10.20 | |
| Iovance Biotherapeutics (IOVA) | 1.6 | $3.9M | 150k | 26.02 | |
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 1.5 | $3.8M | 561k | 6.73 | |
| Syndax Pharmaceuticals (SNDX) | 1.4 | $3.5M | 206k | 17.17 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 1.3 | $3.3M | 370k | 8.99 | |
| Gh Research Ordinary Shares (GHRS) | 1.3 | $3.3M | 150k | 21.73 | |
| Aclaris Therapeutics (ACRS) | 1.2 | $3.1M | 175k | 17.56 | |
| Catalyst Biosciences Com New | 1.2 | $3.0M | 685k | 4.33 | |
| Sage Therapeutics (SAGE) | 1.2 | $2.9M | 51k | 56.81 | |
| Rain Therapeutics | 1.0 | $2.5M | 162k | 15.54 | |
| Catabasis Pharmaceuticals In Com New | 1.0 | $2.5M | 1.2M | 2.11 | |
| Catalyst Pharmaceutical Partners (CPRX) | 0.8 | $1.9M | 329k | 5.75 | |
| Avidity Biosciences Ord (RNA) | 0.6 | $1.5M | 60k | 24.72 | |
| Reata Pharmaceuticals Cl A | 0.6 | $1.4M | 10k | 141.50 | |
| Cymabay Therapeutics | 0.5 | $1.3M | 302k | 4.36 | |
| Novavax Com New (NVAX) | 0.2 | $491k | 2.3k | 212.09 | |
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.1 | $236k | 91k | 2.60 |
